[1]
|
R. D. Zenoble and R. J. Kemppainen, “Adrenocortical Suppression by Topically Applied Corticosteroids in Healthy Dogs,” Journal of American Veterinary Medical Association, Vol. 191, No. 6, 1987, pp. 685-688.
|
[2]
|
Fluocinonide, United States Pharmacopeia USP32 NF 27, 2009, pp. 2401-2403.
|
[3]
|
E. Shek, J. Bragonje, E. J. Benjamin, M. J. Sutherland and J. A. P. Gluck, “A Stability Indicating High-Performance Liquid Chromatography Determination of Triple Corticoid Integrated System in a Cream,” International Journal of Pharmaceutics, Vol. 11, No. 3, 1982, pp. 257-269.
|
[4]
|
E. Bailey and P. N. Brittain, “The Quantitative Determination of Fluocinolone Acetonide and Acetonide Acetate in Formulated Products by High Pressure Liquid Chromatography,” Journal of Pharmacy and Pharmacology, Vol. 24, No. 6, 1972, pp. 425-428.
|
[5]
|
W. C. Landgraf and E. C. Jennings, “Steroid Determination from Complex Mixtures by High Pressure Chroma- tographic Techniques,” Journal of Pharmaceutical Sciences, Vol. 62, No. 2, 1973, pp. 278-281.
|
[6]
|
F. Biley, A. Holbrook and R. J. Miller, “The Determina- tion of Fluocinolone Acetonide in Formulated Products,” Journal of Pharmacy and Pharmacology, Vol. 18, 1966, pp. 12S-16S.
|
[7]
|
M. Bakshi and S. Singh, “Development of Validated Stability Indicating Assay Methods—Critical Review,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 28, No. 6, 2002, pp. 1011-1040.
|
[8]
|
P. Srinivasu, D. V. Subbarao, R. V. K. Vegesna, K. S. Babu, “A Validated Stability Indicating LC Method for Acetazolamide in the Presence of Degradation Products and Its Process Related Impurities,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 52, No. 1, 2010, pp. 142-148.
|
[9]
|
D. V. Subbarao, P. Radhakrishnanand and V. Himabindu, “Stress Degradation Studies on Tadalafil and Development of a Validated Stability Indicating LC Assay for Bulk Drug and Pharmaceutical Dosage Form,” Chromatographia, Vol. 67, No. 1-2, 2008, pp. 183-188.
|
[10]
|
D. V. Subbarao, P. Radhakrishnanand, M. V. Suryanarayana and V. Himabindu, “A Stability Indicating LC Method for Candesartan Cilexetil,” Chromatographia, Vol. 66, No. 7-8, 2007, pp. 499-507.
|
[11]
|
A. Madhavi, D. V. Subbarao, P. Srinivasu and A. Naidu, “Development and Validation of a New Analytical Method for the Determination of Related Components and Assay of Ranolazine in Bulk Drug and Pharmaceutical Dosage Forms by LC,” Chromatographia, Vol. 70, No. 1-2, 2009, pp. 333-338.
|
[12]
|
A. Madhavi, A. Naidu, D. V. Subbarao and P. Srinivasu, “Development and Validation of a New LC Method for the Analysis of Determination of Brimonidine Tartrate and Related Components,” Chromatographia, Vol. 69, No. 11-12, 2009, pp. 1413-1419.
|
[13]
|
J. T. Carstensen and C. T. Rhodes, “Drug Stability Principles and Practices,” 3rd Edition, Marcel Dekker, New York, 2000.
|
[14]
|
U.S. Food and Drug Administration, “ICH Guidelines on Validation of Analytical Procedures: Text and Methodology Q2 (R1),” Federal Register, FDA, Silver Spring, 2005.
|
[15]
|
International Federation of Pharmaceutical Manufactures & Associations, “ICH Stability Testing of New Drug Substances and Products Q1A (R2),” International Conference on Harmonization, Geneva, 2003.
|